Intravenous Immunoglobulin Market Share, Size, Demand And Future challenges
Global Intravenous Immunoglobulin Market Size- By Application, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: May-2025 | Report ID: HLCA25156 | Pages: 1 - 262 | Formats*: |
| Category : Healthcare | |||
Intravenous Immunoglobulin Market Introduction and Overview
According to SPER Market Research, the Global Intravenous Immunoglobulin Market is estimated to reach USD 28.52 billion by 2034 with a CAGR of 7.49%.
The global intravenous immunoglobulin market is expected to reach USD XX billion by 2024, growing at a XX% CAGR during the projected period. The market is being driven by the increasing occurrence of autoimmune illnesses, immunodeficiencies, and neurological diseases such as primary immunodeficiency (PID), chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain-Barre syndrome. Increased awareness and improvements in immunotherapy, combined with an older population that is more vulnerable to immune-related illnesses, drive market expansion. Intravenous Immunoglobulin (IVIG) therapies are in high demand due to their efficacy as the principal treatment for both acquired and primary immunodeficiencies. With no other treatment choices available, IVIG is an important therapy for addressing these illnesses.
In March 2024: Argenx SE reported that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved VYVGART (efgartigimod alfa) for intravenous (IV) use in people with primary immune thrombocytopenia (ITP).
In January 2024: The FDA has authorized GAMMAGARD LIQUID for the treatment of neuromuscular impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It is administered as an induction therapy, followed by maintenance dosages. However, it has not been investigated in immunoglobulin-naive individuals or as a maintenance therapy for more than six months.
By Application:
The intravenous immunoglobulin (IVIG) market is divided into immunodeficiency illnesses, CIDP, Hypogammaglobulinemia, congenital AIDS, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, ITP, Kawasaki disease, Guillain-Barre syndrome, and others. The immunodeficiency diseases segment had the highest revenue share of 19.78% in 2024. The increased frequency of primary and acquired immunodeficiency disorders (PID and AID) is driving the expansion of immunodeficiency diseases; therapy with IV antibiotics is frequently required to manage infections. IVIG replacement therapy is the most effective treatment option for immunodeficiency illnesses, resulting in consistent market growth in the coming years. The Kawasaki disease category is predicted to expand the quickest in the market over the forecast period.
By Distribution Channel:
The intravenous immunoglobulin (IVIG) market is divided into three categories: hospital pharmacy, specialty pharmacies, and others. The hospital pharmacy segment had the highest revenue share of 57.33% in 2024. Hospital pharmacies are a convenient choice for patients due to their broad network and diverse product offerings. Furthermore, the rising prevalence of primary immunological deficiencies, hepatitis C, and other disorders has resulted in an increase in hospitalizations worldwide, driving increased patient preference for hospital pharmacies. Hospitals also provide speedy reimbursement processes, excellent treatment, and complete care, which contribute to the growing number of patients choosing hospital pharmacies.
By Regional:
In 2024, North America dominated the intravenous immunoglobulin (IVIG) market, accounting for 46.11% of the global total. North America is the main region for intravenous immunoglobulin (IVIG), accounting for 46.11% of the global market in 2024. This market is expanding rapidly, owing to rising demand for IVIG therapies to treat a wide range of immunodeficiency illnesses and related conditions. The growing use of IVIG pharmacies also helps to expand access to medication throughout the region.
Market Competitive Landscape:
These companies invest in research, manufacturing capacity, and global expansion to address the growing demand for IVIG medicines. Some of the market players are Baxter, BDI Pharma Inc., Biotest AG, China Biologics Products Inc., CSL, Grifols SA, Kedrion, LFB, Octapharma AG and others.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Application, By Distribution Channel |
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe |
| Companies Covered | Baxter, BDI Pharma Inc., Biotest AG, China Biologics Products Inc., CSL, Grifols SA, Kedrion, LFB, Octapharma AG and others. |
- Global Intravenous Immunoglobulin Market Size (FY 2025-FY 2034)
- Overview of Global Intravenous Immunoglobulin Market
- Segmentation of Global Intravenous Immunoglobulin Market By Application (Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis and Multifocal motor neuropathy)
- Segmentation of Global Intravenous Immunoglobulin Market By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies and Other)
- Statistical Snap of Global Intravenous Immunoglobulin Market
- Expansion Analysis of Global Intravenous Immunoglobulin Market
- Problems and Obstacles in Global Intravenous Immunoglobulin Market
- Competitive Landscape in the Global Intravenous Immunoglobulin Market
- Details on Current Investment in Global Intravenous Immunoglobulin Market
- Competitive Analysis of Global Intravenous Immunoglobulin Market
- Prominent Players in the Global Intravenous Immunoglobulin Market
- SWOT Analysis of Global Intravenous Immunoglobulin Market
- Global Intravenous Immunoglobulin Market Future Outlook and Projections (FY 2025-FY 2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1.Global Intravenous Immunoglobulin Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Intravenous Immunoglobulin Market
7. Global Intravenous Immunoglobulin Market, By Application (USD Million) 2025-2034
- 7.1. Immunodeficiency diseases
- 7.2. CIDP
- 7.3. Hypogammaglobulinemia
- 7.4. Congenital AIDS
- 7.5. Chronic Lymphocytic Leukemia
- 7.6. Myasthenia Gravis
- 7.7. Multifocal motor neuropathy
8. Global Intravenous Immunoglobulin Market, By Distribution Channel (USD Million) 2025-2034
- 8.1. Hospital Pharmacies
- 8.2. Specialty Pharmacies
- 8.3. Other
9. Global Intravenous Immunoglobulin Market Forecast, 2025-2034 (USD Million)
- 9.1. Global Intravenous Immunoglobulin Market Size and Market Share
10. Global Intravenous Immunoglobulin Market, By Region, 2025-2034 (USD Million)
- 10.1. Asia-Pacific
- 10.1.1. Australia
- 10.1.2. China
- 10.1.3. India
- 10.1.4. Japan
- 10.1.5. South Korea
- 10.1.6. Rest of Asia-Pacific
- 10.2. Europe
- 10.2.1. France
- 10.2.2. Germany
- 10.2.3. Italy
- 10.2.4. Spain
- 10.2.5. United Kingdom
- 10.2.6. Rest of Europe
- 10.3. Middle East and Africa
- 10.3.1. Kingdom of Saudi Arabia
- 10.3.2. United Arab Emirates
- 10.3.3. Qatar
- 10.3.4. South Africa
- 10.3.5. Egypt
- 10.3.6. Morocco
- 10.3.7. Nigeria
- 10.3.8. Rest of Middle-East and Africa
- 10.4. North America
- 10.4.1. Canada
- 10.4.2. Mexico
- 10.4.3. United States
- 10.5. Latin America
- 10.5.1. Argentina
- 10.5.2. Brazil
- 10.5.3. Rest of Latin America
11. Company Profile
- 11.1. Baxter
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
- 11.2. BDI Pharma Inc.
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
- 11.3. Biotest AG
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
- 11.4. China Biologics Products Inc.
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
- 11.5. CSL
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
- 11.6. Grifols SA
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
- 11.7. Kedrion
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
- 11.8. LFB
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
- 11.9. Octapharma AG
- 11.9.1. Company details
- 11.9.2. Financial outlook
- 11.9.3. Product summary
- 11.9.4. Recent developments
- 11.10. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Intravenous Immunoglobulin Market is projected to reach USD 28.52 billion by 2034, growing at a CAGR of of 7.49% during the forecast period.
Intravenous Immunoglobulin Market grew in Market size from 2025. The Market is expected to reach USD 28.52 billion by 2034, at a CAGR of 7.49% during the forecast period.
Intravenous Immunoglobulin Market CAGR of 7.49% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Intravenous Immunoglobulin Market size is USD 28.52 billion from 2025 to 2034.
Intravenous Immunoglobulin Market is covered By Application, By Distribution Channel
The North America, Asia-Pacific, Latin America, Middle East & Africa and Europe is the highest Market share in the Intravenous Immunoglobulin Market.
Baxter, BDI Pharma Inc., Biotest AG, China Biologics Products Inc., CSL, Grifols SA, Kedrion, LFB, Octapharma AG and others.
The market is being driven by the increasing occurrence of autoimmune illnesses, immunodeficiencies, and neurological diseases such as primary immunodeficiency (PID), chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain-Barre syndrome.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
